The future of anticoagulation clinics: A journey to thrombosis centers?

Haematologica

Volumn 90, Issue 3, 2005, Pages 298-301

  Marongiu, Francesco ^a   Barcellona, Doris ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; COUMARIN; IDRAPARINUX; LUPUS ANTICOAGULANT; MELAGATRAN; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; EDITORIAL; EMBOLISM PREVENTION; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; PATIENT COMPLIANCE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; FORECASTING; HEALTH FACILITIES; HUMANS; POPULATION SURVEILLANCE; THROMBOSIS;

EID: 15244351936     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (55)

1. Mannucci PM, Poller L. Venous thrombosis and anticoagulant therapy. Historical review. Br J Haematol 2001;114:258-70.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126:204S-33S.
3. Poller L. The standardisation of oral anticoagulant treatment. The Manchester Regional Thromboplastin Scheme. Br Med J 1964;2:565-6.
4. Kirkwood TBL. Calibration of reference thromboplastin and standardisation of the prothrombin time ratio. Thromb Haemost 1983;36:230-6.
5. Poller L. International Normalized Ratio (INR): the first 20 years. J Thromb Haemost 2004;2:849-60.
6. Berrettini M. Anticoagulation clinics: the Italian experience. Haematologica 1997;82:713-7.
7. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
8. Palareti G, Manotti C, DAngelo A, Pengo V, Erba N, Moia M, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997;78:1438-43.
9. Pengo V, Legnani C, Noventa F, Palareti G. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost 2001;85:418-22.
10. Pengo V, Barbero F, Banzato A, Garelli E, Noventa F, Biasiolo A, et al. A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses. Thromb Haemost 1997; 77:839-44.
11. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-10.
12. Palareti G, Hirsh J, Legnani C, Manotti C, D'Angelo A, Pengo V, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000; 28: 470-8.
13. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001;86:1060-70.
14. Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F. The management of oral anticoagulant therapy: the patient's point of view. Thromb Haemost 2000;83:49-53.
15. A guide to oral anticoagulant treatment. Haematologica 2003; 88 Suppl 2:1-47.
16. Tripodi A, Chantarangkul V, Mannucci PM. Near-patient testing devices to monitor oral anticoagulant therapy. Br J Haematol 2001;113:847-52.
17. Self-testing and self management of oral anticoagulant therapy: consensus of the italian federation of anticoagulation clinics. Haematologica 2003 Suppl 3;88:1-10.
18. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003;254:322-34.
19. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1:2490-6.
20. Schulman S, Wahlander K, Lundstrom T Clason SB, Eriksson H. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
21. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003;362:1691-98.
22. Verheugt FW. Can we pull the plug on warfarin in atrial fibrillation? Lancet 2003;362:1686-7.
23. Herbert JM, Herault JP, Bernat A, van Asterdam RG, Lormean JC, Petitou M. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998;91:4197-205.
24. Donnan GA, Dewey HM, Chambers BR. Warfarin for atrial fibrillation: the end of an era ? Lancet Neurol 2004;3:305-8.
25. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg 3006) to replace warfarin for the secondary prevention of deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004;2:47-53.
26. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002;105: 2385-91.
27. Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, et al. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004;2:234-41.
28. Hankey GJ. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management or patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc Dis 2004;17 Suppl 3:11-6.
29. Cauli C, Barcellona D, Marongiu F. Oral anticoagulant therapy in the primary and secondary prophylaxis of stroke. Ital Heart J 2003;4:755-67.
30. Ruivard M, Berger C, Achaibi A Campagne C, Philippe P. Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. J Gen Intern Med 2003;18: 903-7.
31. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
32. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth 2002;49:S11-25.
33. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004; 41 Suppl 1:65-9.
34. Pearson RM. Who is taking their tablets? Br Med J 1982;285: 757-8.
35. van der Meer FJ, Briet E, Vandenbroucke JP, Sramek DI, Versluijs MR, Rosendaal FR. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997;98:893-900.
36. Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. Haematologica 2002;87:1081-6.
37. Marongiu F, Sorano GG, Conti M, Mameli G, Biondi G, Licheri D, et al. Known vitamin K intake and management of poorly controlled oral anticoagulant therapy. Lancet 1992;340: 545-6.
38. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
39. Barcellona D, Fenu L, Marongiu F. Oral anticoagulant therapy: should doctors change the way they give explanations to patients? Thromb Haemost 2003;90:159-60.
40. Koopman MMW, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254:335-42.
41. Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci PM. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations. A cause of concern. Thromb Haemost 2002;88: 690-1.
42. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003;49: 1608-14.
43. Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci Pm, Cattaneo M. Multicenter study of homocysteine measurement: performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost 2001;85:291-5.
44. D'Angelo A, Mazzola G, Crippa L, Fermo I, Viganò D'Angelo S. Hyperhomocysteinemia and venous thromboembolic disease. Haematologica 1997;82:211-9.
45. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-76.
46. Faioni EM. Reliable estimates of plasma protein S levels: are we getting closer ? Thromb Haemost 2001;86:1139-40.
47. D'Angelo A and Piovella F. Optimal duration of oral anticoagulation therapy after a first episode of venous thromboembolism: where to go? Haematologica 2002;87:1009-13.
48. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-8.
49. Remy-Jardin M, Mastora I, Remy J. Pulmonary embolus imaging with multislice CT. J Radiol Clin North Am 2003;41:507-19.
50. Coche E, Verschuren F, Keyeux A, Goffette P, Goncette L, Hainaut P, et al. Diagnosis of acute pulmonary embolism in outpatients: comparison of thin-collimation multi-detector row spiral CT and planar ventilation-perfusion scintigraphy. Radiology 2003;229:757-65.
51. Ghaye B, Remy J, Remy-Jardin M. Non-traumatic thoracic emergencies: CT diagnosis of acute pulmonary embolism: the first 10 years. Eur Radiol 2002;12:1886-905.
52. Schoepf UJ, Bruening R, Konschitzky H, Becker Cr, Knez A, Weber J, et al. Pulmonary embolism: comprehensive diagnosis by using electron-beam CT for detection of emboli and assessment of pulmonary blood flow. Radiology 2000;21:693-700.
53. van Beek EJ, Wild JM, Fink C, Moody AR, Kauczor HU, Oudkerk M. MRI for the diagnosis of pulmonary embolism. J Magn Reson Imaging 2003;18:627-40.
54. Moll S. Use of combined CT venography and CT pulmonary arteriography. J Thromb Haemost 2003;1:637.
55. Moffat BA, Reddy GR, McConville P, Hall De, Chenevert TL, Kopelman RR, et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003;2:324-32.